Multidisciplinary treatment of pain caused by bone metastases in cancer patients: two case reports by Cichowska-Cwalińska, Natalia & Zaucha, Renata
142
Case report
NOWOTWORY Journal of Oncology
2017, volume 67, number 2, 142–145 
DOI: 10.5603/NJO.2017.0023 
© Polskie Towarzystwo Onkologiczne
ISSN 0029–540X
www.nowotwory.edu.pl
Department of Clinical Oncology and Radiotherapy, Medical University of Gdańsk, Poland
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metastases in cancer patients: two case reports
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Over 50% patients with malignant neoplasms suffer pain. In Poland, about 200,000 people annually have to contend 
with this problem. It can arise from the prolonged lifespan of cancer patients, the development of iatrogenic pain 
syndromes, pain associated with cancer cachexia, or decreased efficacy of analgesics due to induced opioid toler-
ance. The commonly used term “cancer pain” actually refers to all types of pain. In order that each patient is optimally 
treated, it is necessary to identify the type and cause of their pain. One of the more difficult types of pain to treat 
is that due to bone metastases; with its inflammatory and neuropathic components. Every patient has the right to 
proper pain treatment, with the goal of achieving the maximum analgesic effect while minimizing any side effects.
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Introduction
Pain in cancer patients is a very complex phenomenon. 
It is primarily the result of proliferative disease, but also due 
to intense and sometimes aggressive oncological treatment. 
This is why about 30% of recovered patients experience 
such pain [1]. Cancer patients are living increasingly longer 
and are more likely to develop iatrogenic pain syndromes, 
cachexia-induced pain or decreased efficacy of analgesics 
due to opioid tolerance. In order to establish optimal treat-
ments for each patient, it is necessary to identify the type 
and cause of their pain. According to the neurophysiological 
classification, pain can be distinguished into pain due to 
receptors (conjunctive pain) or neuropathic pain. Both are 
caused by mechanical or chemical sensitization of sensory 
receptors, with the difference that nociceptive pain arises in 
a properly functioning system of detection, conduction and 
modulation of pain whilst neuropathic pain shows evidence 
of damage to the nervous system, often by tumors or dam-
aged bone structures. Conjunctive pain usually responds 
well to non-opioid analgesics and opioids as opposed to 
neuropathic pain which is resistant to analgesics, frequently 
requiring additional medication or other methods. Vari-
ous tools are used to assess pain intensity. The easiest for 
patients and therefore the most commonly used tool is the 
numerical rating score (NRS), which consists of 11 degrees 
of pain intensity ranging from 0 to 10, where 0 signifies the 
total absence of pain, and 10 is the worst possible pain.
One of the more difficult types of pain to treat is pain due 
to bone metastasis, with its inflammatory and neuropathic 
components. It is the most common pain with a dominant 
somatic mechanism, which is the result of activation of the 
sensory and sympathetic innervation of the periosteum, 
bone tissue and bone marrow by a series of substances 
released by the tumor and immune cells. This also becomes 
exacerbated by other disorders such as osteolysis of the 
bones, which irritates nociceptors that respond to a drop in 
pH, or periosteal extension in the case of unstable fractures 
[2]. Sometimes, nerve growth factor (NGF) is released by 
the tumor cells, which results in nerve fiber growth in the 
bone itself, resulting in a neuropathic component that is 
very difficult to treat [2].
Case no 1
A 61-year-old patient was admitted to the accident and 
emergency (A&E) department of a Gdańsk hospital due 
to an episode of very severe lumbar spine pain, in July 
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2015. This pain had been treated for several months with 
non-steroidal anti-inflammatory analgesics. She received as 
needed, adjuvant ketoprofen 100 mg up to 5 times daily. 
The patient was additionally treated for hypertension which 
was well controlled by taking enalapril 10 mg daily. In 2003, 
she had resection of IV and V segments of the left lung due 
to lung cancer (adenocarcinoma, G1, pT1aN0M0). In 2004, 
she then had a hysterectomy because of uterine fibroids. 
She has never smoked any tobacco products. 
Magnetic resonance imaging (MR) showed a prolifera-
tive lesion of the L4 vertebral body, which could correspond 
to a primary or secondary osteosclerotic lesion. This could 
be a primary process or a secondary osteosclerotic change. 
In August 2015, a resection of the L4 pathological mass 
was performed at the Department of Neurosurgery, with 
simultaneous cementoplasty and transpedicular stabili-
zation of L3–L5 vertebral bodies. Histopathological results 
clearly defined the nature of the lesion as a metastatic ad-
enocarcinoma with the most likely exit point being from 
lung tissue (TTF1+). Diagnostics included positron emis-
sion tomography (PET/CT) which showed the presence of 
a metabolically active proliferative process in the upper 
lobe of the left lung, measuring 33 mm × 19 mm (SUV up 
to 9.8) with dissemination to the skeletal system. The largest 
osteosclerotic changes were seen in the bones of the pelvis 
and in the vertebrae of the lumbar spine.
As this adenocarcinoma was diagnosed in a non-smoker, 
the patient was then tested for EGFR gene mutation in exons 
18, 19, 20 and 21, and the arrangement of the ALK and ROS-1 
gene was also determined. Negative results of the molecular 
studies disqualified the patient from targeted treatment. 
The patient reported severe pain in the sternum area as 
well as the left hip radiating to the left lower limb. The pain 
was described as being acute, paroxysmal, waking her from 
sleep, with paresthesias of an intensity score of 6 on the 
NRS (numerical rating scale) of up to 10 point exacerbation 
scores. The patient was taking oxycodone — 10 mg as need-
ed, and ketoprofen 100 mg 1 × daily. Physical examination 
confirmed bone pain with a neuropathic component. Due 
to the ineffectiveness of the pain treatment, regular oral 
administration of opioids was recommended, i.e. oxycodone 
2 × 20 mg with paracetamol 2 × 1 g daily. Additionally, the 
co-analgesic pregabalin was orally prescribed 75 mg twice 
daily. A satisfactory analgesic effect in the area of prima-
ry pain was obtained. Nevertheless, the patient reported 
very strong breakthrough pain. This pain, on the NRS scale, 
reached the highest values (9–10), had an acute onset (2–3 
minutes) and lasted for about 30 minutes. It appeared with-
out any specific cause, up to 4 times daily. Due to the de-
scribed nature of the pain, it was advised to use an adjuvant 
water-based formulation of fentanyl intranasally at 100 mg 
per dose. This supplementation brought about very satis-
factory pain relief within minutes. Systemic treatment was 
implemented: palliative chemotherapy with pemetrexed 
500 mg/m2 i.v. and cisplatin 50 mg/m2 i.v. every 21 days. 
Palliative radiotherapy was used for the areas of major pain 
in the sternum and left hip, using 20 Gy electron and photon 
fields in 4 fractions respectively. After two weeks, the pain 
was significantly reduced in the irradiated areas. Episodes 
of breakthrough pain occurred much less frequently of up 
to twice daily maximum. Bisphosphonates (zoledronic acid) 
were also used to induce osteoclast inactivation.
Case no 2
A 22-year-old patient was admitted to the A&E depart-
ment of a Gdańsk hospital after falling of a bicycle, injuring 
her right ankle and left ribcage. During the physical exami-
nation, ecchymoses were found in the vicinity of the injuries. 
No significant abnormalities were observed by laboratory 
testing. Diagnostic imaging via X-ray (XR) of both the ankle 
joint and chest were performed, and no fractures were seen. 
In the chest XR, widening of the mediastinum was noted. 
Further diagnostics led to the diagnosis of Ewing’s sarcoma/ 
/PNET atclinically advanced stage III. The patient was quali-
fied for standard systemic treatment according to the VCD/ 
/IE scheme (doxorubicin, cyclophosphamide, vincristine/ 
/ifosfamide, etoposide). Before initiating chemotherapy, 
a left-sided ovarectomy was performed with the goal of 
cryopreserving the ovarian tissue. 
After the second cycle, it was essential to transfuse 
packed red blood cells due to anemia. Diagnostic imag-
ing after the fourth cycle showed partial regression of the 
tumor. Unfortunately, after the next cycle — the fifth VCD, 
a rapid progression was seen. Second-line chemotherapy 
was initiated (doxorubicin, cisplatin), however this proved 
unable to prevent the drastic spread of the tumor within 
the chest and mediastinum, along with metastasis to the 
bones; primarily osteolytic in nature. Laboratory testing 
confirmed hypercalcemia — 12 mg/dL, as well as hypo-
kalemia — 2.8 mmol/L. Clinically, signs of superior vena 
cava syndrome were noted, along with severe nausea and 
vomiting, as well as diarrhea. The patient complained of 
pain in the right shoulder and around the sternum, rating 
an 8 on the NRS, with acute attacks of a dull pain at 10/10 
NRS. Daily tramadol at 2 × 100 mg daily, plus paracetamol + 
codeine (500 mg + 30 mg) 2 × day did not relieve her pain. 
Due to the increased intensity of the primary pain, it was 
decided to discontinue the oral weak opioid analgesics. In 
exchange, titrated morphine was given subcutaneously. 
After establishing an adequate daily dose, conversion to 
a transdermally applied dose in the form of a fentanyl patch 
was given at 50 mg/h. Non-steroidal anti-inflammatory an-
algesics were added — ketoprofen 100 mg 2 × d as well as 
corticosteroids in the form of dexamethasone 4 mg 3 × d. 
Due to the hypercalcemia, bisphosphonate supplemen-
tation (zolendronic acid) was given. Improvement in pain 
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relief from the primary location was obtained, however the 
spontaneous breakthrough pain (9–10 NRS) was not well 
controlled. Initially, morphine was additionally given orally 
in 20mg doses about every 4 hours. This did not relieve the 
breakthrough pain entirely, and the patient complained of 
increased side effects (nausea and vomiting, constipation). 
Oral morphine was discontinued and intranasal fentanyl in 
a water-based formulation was given at doses of 100 mg/ 
/dose, as and when required. This change in medication 
brought about the expected analgesic effect. The patient 
required about 2–4 additional applications of this rescue 
medication to achieve complete pain relief. Immediately 
after stabilization of both the patient’s general status and 
laboratory parameters, the patient was qualified for pallia-
tive radiotherapy of the mediastinum due to superior vena 
cava syndrome. After completing radiation therapy, she 
still requires multiple analgesics to treat her pain. Due to 
the invasion of almost the entire skeletal system, palliative 
radiotherapy for pain relief was not performed.
Conclusions
In contrast to primary neoplasms of the bone, which 
are rare, secondary metastasis to the bones is diagnosed 
in 70% of patients. Bone pain is often the first symptom of 
a generalized disease. Metastasis to the bone also threatens 
the patient’s health with pathological fractures or spinal 
cord compression syndrome, which may require palliative 
radiotherapy or surgical intervention.
Pharmacotherapy of bone pain is classically treated 
with the three-step ladder of analgesia [3]. First line therapy 
includes non-steroidal anti-inflammatory drugs as well as 
opioids. It is important to remember to give these medica-
tions at the proper time intervals, as well as not giving weak 
opioids together with strong opioids. Due to the common 
characteristic of neuropathic pain, co-analgesics are often 
recommended such as anti-epileptics or anti-depressants [4]. 
It has been confirmed that anti-osteolytic medications, such 
as bisphosphonates, also have an analgesic effect. They can 
also be used to lower the serum calcium concentration [5]. 
Other anti-osteolytic medications with a confirmed anal-
gesic effect include human molecular anti-bodies (IgG2) 
targeted against RANK-L and preventing activation of this 
receptor (receptor activating nuclear factor NF-kB) on the 
surface of osteoclasts and their precursors. At present, there 
is no evidence regarding the superiority of denozumab 
when compared to bisphosphonates for delivering an an-
algesic effect. It is known that denozumab is more effective 
at preventing adverse bone occurrences. Its use is related to 
a decreased risk of kidney damage or acute phase reactions, 
a similar risk of osteonecrosis of the jaw, and an increased 
risk of hypercalcemia [6].
In certain situations, it is standard practice to use anti- 
-edema drugs such as corticosteroids. For such cases it is 
essential to use the appropriate route of administration and 
to prevent possible side effects such as bleeding from the 
gastrointestinal tract, immunosuppression leading to an 
increased risk of infection, or an impaired glucose tolerance. 
Effective systemic palliative treatment decreases the intensi-
ty of symptoms related to malignancies. The most effective 
of these is palliative radiotherapy, which brings about a very 
satisfactory local analgesic effect in 85% of patients, and 
a complete resolution of pain symptoms in about 15–60% of 
patients [7]. The analgesic effect, brought about as a result 
of the destruction of radiation-sensitive macrophages and 
osteoclasts, is independent of the histopathological type 
of cancer [8]. Such treatments can be given in 1, 4 or 5 frac-
tions. Besides traditional radiotherapy, when treating bone 
metastases, stereotactic radiotherapy (SABRT) can also be 
used. This method is mainly emplyed in oligometastatic 
disease (1 to 3 metastatic foci) as well as in cases of metas-
tasis localized around organs easily damaged by ionizing 
radiation, such as the spinal cord. SABRT not only delivers 
a quick reduction in pain intensity and improvement in 
neurological function in spinal cord compression syndrome, 
but thanks to the dramatically decreased dose outside of 
the irradiated field, the risk of damage to the spinal cord is 
diminished and additionally, it spares the bone marrow [9]. 
SABRT obviously does not repair compression fractures nor 
does it stabilize the spine.
In cases of multiple metastases to the bones, radioiso-
topes can be used, like stront or samar [10, 11]. This kind of 
therapy is of a similar analgesic efficacy as teleradiotherapy. 
In cases of invasion of the entire skeleton, radioisotope 
therapy or radiation of half of the body in a single fraction 
can be used. However, it is important to remember that each 
method can cause long-lasting myelosuppression which 
can make the use of chemotherapy impossible. It has been 
shown that using radium chloride in patients with castra-
tion resistant prostatic cancer, not only delivers an analgesic 
effect but also significantly prolongs the overall survival, 
drastically improving the patient’s quality of life; such treat-
ment not being available in Poland [12].
In cases with an increased risk of fracture, or the occur-
rence of a fracture, spinal cord compression syndrome may 
require orthopedic or neurosurgical intervention and care 
as well as rehabilitation. It is essential to work together as 
a multi-disciplinary team, together with providing individu-
alized therapy.
Studies show that in Poland over 75% of patients with 
pain due to malignant neoplasms do not obtain satisfactory 
pain relief [13]. Proof of this can be seen in the 20-fold lower 
usage of morphine equivalents in kg per capita in Poland 
when compared to countries with a similar population such 
as Canada.
Problems related to pain management are still a relevant 
issue and require further refinement in the education of 
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both medical students and physicians, independent of their 
specialization(s).
Conflict of interest: none declared
Prof. Renata Zaucha, MD, PhD
Department of Clinical Oncology and Radiotherapy
Medical University of Gdańsk
7 Debinki St., 80–211 Gdańsk, Poland
e-mail: rzaucha@gumed.edu.pl
Received: 4 Aug 2016 
Accepted: 15 Mar 2017 
References
1. Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach 
złośliwych 2013 rok. T. 1. Krzakowski M, Warzocha K (ed.). Gdańsk: Via 
Medica, 2013.
2. Stany nagłe w onkologii — występowanie i leczenie. T. II. Szawłowski A, 
Wallner G (ed.). Poznań: Termedia Wydawnictwa Medyczne, 2015.
3. WHO. Cancer pain relief: with a guide to opioid availability. 2nd ed. 
Geneva: World Health Organization, 1996.
4. Saarto T, Wiffen P. Antidepressants for neuropathic pain (Cochrane 
Review). Cochrane Database Syst Rev 2007; (4): CD005454.
5. Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary 
to bone metastases. Cochrane Database Syst Rev 2002; (2): CD002068.
6. Sivolella S, Lumachi F, Stellini E et al. Denosumab and anti-angiogenetic 
drug-related osteonecrosis of the jaw: an uncommon but potentially 
severe disease. Anticancer Res 2013; 33: 1793–1797.
7. van der Velden JM, Verkooijen HM, Seravalli E et al. Comparing con-
ventional radiotherapy with stereotactic body radiotherapy in patients 
with spinal metastases: study protocol for an randomized controlled 
trial following the cohort multiple randomized controlled trial design. 
BMC Cancer 2016; 16: 909.
8. Yamada Y, Katsoulakis E, Laufer I et al. The impact of histology and 
delivered dose on local control of spinal metastases treated with stereo-
tactic radiosurgery. Neurosurg Focus 2017; 42: E6. doi: 10.3171/2016.9. 
FOCUS16369.
9. Schipani S, Wen W, Jin JY et al. Spine radiosurgery: A dosimetric analysis 
in 124 patients who received 18Gy. Int J Radiat Oncol Biol Phys 2012; 
84: e571–576.
10. Oosterhof GO, Roberts JT, de Reijke TM et al. Strontium(89) chloride 
versus palliative local field radiotherapy in patients with hormonal 
escaped prostate cancer: a phase III study of the European Organisation 
for Research and Treatment of Cancer, Genitourinary Group. Eur Urol 
2003; 44: 519–526.
11. Roqué I Figuls M, Martinez-Zapata MJ, Scott-Brown M et al. Radioiso-
topes for metastatic bone pain. Cochrane Database Syst Rev 2011; (7): 
CD003347.
12. Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and 
survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213–223.
13. Deandrea S, Montanari M, Moja L et al. Prevalence of undertreatment 
in cancer pain. A review of published literature. Ann Oncol 2008; 19: 
1985–1991.
14. www.treatthepain.org.
